SLC5A2 and heart failure: Empagliflozin treatment produced no substantial changes in six-minute walk distance exercise capacity, according to McMurray et al. and Solomon et al., which established that dapagliflozin treatment had no meaningful effect on exercise function [29,36]. The beneficial effects of SGLT2 inhibitors demonstrated in heart failure symptom reduction and hospital admission prevention do not necessarily yield improvements in patient exercise capacity.